Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ・ALNY has a 100% technical ...

Decline in Revenue: Over the 3 months period, Alnylam Pharmaceuticals faced challenges, resulting in a decline of approximately -33.26% in revenue growth as of 30 September, 2024.

Fintel reports that on August 4, 2025, Oppenheimer upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from Perform to Outperform. Analyst Price Forecast Suggests 18.88% Downside As of ...

In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $420.41, a high estimate of $570.00, and a low estimate of $333. ...

Alnylam Pharmaceuticals's Current Market Status With a volume of 446,657, the price of ALNY is up 0.74% at $233.99. RSI indicators hint that the underlying stock may be oversold.

UCSF has joined a growing network devoted to combating primary hyperoxaluria. As part of this initiative, patients can now ...

Morgan Stanley cut their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating for the company in a report on Friday, April 11th.

Scotiabank lifted their target price on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the company a “sector outperform” rating in a research report on Friday, March 21st.

Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340 Josh Brodsky (Investors) +1-617-551-8276 ...